Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO con­ga line

Vi­vid­ion is can­cel­ing that IPO it filed. In­stead of fol­low­ing the in­dus­try-wide mi­gra­tion to Nas­daq, the biotech that has cap­tured con­sid­er­able at­ten­tion for its still-pre­clin­i­cal work find­ing cryp­tic pock­ets to bind to on pro­teins is go­ing to work for Bay­er now.

The phar­ma gi­ant is putting out word to­day that it has bought out Vi­vid­ion for $1.5 bil­lion in cash and an­oth­er half-bil­lion dol­lars in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER